Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Morris Elstein

Obstetrics & Gynecology Virginia Beach, VA Medical Doctor

NPI 1285600320 CMS profile 13069

1744 Sir William Osler Dr, Virginia Beach, VA 23454

Open in the dashboard

General payments

$3,639

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morris Elstein of Virginia Beach, VA is reported in the CMS Open Payments database as having received $3,639 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $459 21
2024 General $390 16
2023 General $737 23
2022 General $452 22
2021 General $570 34
2020 General $319 20
2019 General $712 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morris Elstein
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Morris Elstein were reported at $459. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Morris Elstein Obstetrics & Gynecology median Middle half National median
2019 $712 $172 $62–$391 $163
2020 $319 $94 $36–$222 $114
2021 $570 $136 $42–$369 $132
2022 $452 $160 $50–$433 $149
2023 $737 $169 $56–$423 $160
2024 $390 $152 $50–$371 $164
2025 $459 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $779 22 payments
  2. AbbVie, Inc. $765 33 payments
  3. Novo Nordisk Inc $271 9 payments
  4. Merz North America, Inc. $224 4 payments
  5. Currax Pharmaceuticals LLC $206 14 payments
  6. Minerva Surgical, Inc $164 15 payments
  7. Pfizer Inc. $105 7 payments
  8. Exact Sciences Corporation $99 5 payments
  9. Sumitomo Pharma America, Inc. $78 4 payments
  10. Organon LLC $74 4 payments
  11. Other $873 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,420 166 payments
  2. Education $219 4 payments
Products named General payments · program years 2019–2025
  1. Veozah $504 15 payments
  2. Wegovy $258 8 payments
  3. CONTRAVE $206 14 payments
  4. Endometrial Ablation System (Device) $164 15 payments
  5. ORILISSA Womens Health $159 13 payments
  6. ORIAHNN $158 9 payments
  7. Orilissa Endocrinology $125 1 payment
  8. HUMIRA $124 2 payments
  9. PREMARIN $122 8 payments
  10. ESTRING $105 7 payments
  11. Other $1,517 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

292

Median for Obstetrics & Gynecology: 65

Drug cost

$32,922

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

65.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 15 $13,523
Prometrium Progesterone, Micronized Brand 13 $6,399
Estradiol Generic 48 $3,991
Estradiol (Twice Weekly) Estradiol Brand 36 $3,720
Progesterone Progesterone, Micronized Brand 49 $1,863
Norethindrone Acetate Generic 24 $1,143
Valacyclovir Valacyclovir Hcl Brand 23 $936
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 25 $579
Bupropion Xl Bupropion Hcl Brand 12 $277
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 19 $242

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$46,447

Of which drugs: $385

Medicare patients

347

Average age 72

Services billed

23,486

347 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 49%
Osteoporosis 23%
Depression 19%
Diabetes 15%
Cancer 14%
Ischemic heart disease 12%
COPD 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, testosterone cypionate, 1 mg J1071 Office 63 22,382 $376

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $182
$182 — —
Veozah
  • Astellas Pharma US Inc $140
$140 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $14
$14 — —
MYRBETRIQ
  • Astellas Pharma US Inc $7
$7 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record